Three anti-HIV proteins- the antiviral lectin cyanovirin, the antiviral lectin griffithsin, and the monoclonal antibody 2G12- have been successfully expressed in the same rice seed. The co-expression allows for a low cost, stable production method for a triple anti-HIV microbicide for the prevention of HIV. The National Cancer Institute (NCI) seeks licensees for the invention microbicide and production method.
The National Cancer Institute (NCI) Molecular Targets Laboratory is seeking parties interested in collaborative research to co-develop antiviral tropolone derivatives developed by systematic medicinal chemistry on the lead series.
Researchers at the National Cancer Institute (NCI) have engineered a single recombinant phage with dual tail fibers that can target and kill bacteria of different genera. The diversity in phage tail fiber components successfully circumvents previously known limitations on phage host selectivity.
Researchers at the National Cancer Institute (NCI) have developed nucleic-acid-based nanoparticle that can be adapted for RNA interference (RNAi), molecular imaging, or a combination thereof. The invention nanoparticles can be used as therapeutics in the treatment of cancer, whichthe NCI seeks parties to license or co-develop.
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.
Researchers at NCI's Cancer and Inflammation Program developed fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses. The National Cancer Institute's Cancer and Inflammation Program seeks parties interested in licensing fully human monoclonal antibodies as possible therapeutics and prophylactics, as well as a template for a Dengue vaccine.
Researchers at the National Cancer Institute (NCI) have developed an engineered storage unit for frozen tissue, that provides a permanent base on which to mount tissue frozen in OCT and an enclosure for storage. The unit provides for chain-of-custody labeling and acts as an insulating container to protect the specimen. Other elements include devices for freezing the tissue to the base, as well as a holder for the base to facilitate cryosectioning. Application of the storage system allows a frozen tissue specimen to be moved between storage and cryosectioning without loss of label, deformation of tissue, or thermal alterations.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license or co-develop this technology toward commercialization.
Researchers at the National Cancer Institute (NCI) have developed several novel small-molecule inhibitors directed against HPPK, a bacterial protein, as potential antimicrobial agents. The NCI seeks co-development partners or licensees to further develop these novel small-molecule HPPK inhibitors as broad-spectrum bactericidal agents.
Researchers at the National Cancer Institute (NCI) have developed an invention describing novel small molecule agonists of a previously unidentified hepatitis B virus (HBV) RNA packaging signal (pgRNA) as promising therapeutic strategies for HBV infections, either alone or in combination with other antiviral agents. The NCI seeks licensing and/or co-development research collaborations for these novel small molecules that inhibit hepatitis B virus replication by targeting pre-genomic RNA.
Researchers at the National Cancer Institute (NCI) have developed single domain human CD4 proteins to inhibit HIV-1 entry and improved human domain antibodies against HIV-1. Fusion proteins comprising the single domain CD4 and HIV-1 antibody can be used to effectively neutralize HIV-1 in vitro. Researchers seek licensing for development of these antibody-based therapeutics for the treatment of HIV-1.
Researchers at the NCI have developed a method of improving the immune response in cancer immunotherapy by exploiting in the role of the Linker Adapted for T-Cell Signaling (LAT) molecule. The LAT molecular can enhance signaling through TCRs, thus, improving a patient’s own immune response to cancer or infectious diseases.